Skip to content

Impact of Severe Brain Injury on Neuro-vascular and Endothelial Regulation of Peripheral Microcirculation.

Study of the Impact of Severe Brain Injury on the Neuro-vascular and Endothelial Regulation of Peripheral Microcirculation.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04597879
Acronym
MicroTC
Enrollment
30
Registered
2020-10-22
Start date
2021-08-01
Completion date
2023-03-31
Last updated
2022-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Traumatic Brain Injury, Trauma

Keywords

Brain trauma, Severe traumatic brain injury, Microcirculation, Speckle, Post-occlusive reactive hyperaemia

Brief summary

Severe brain injury (SBI) is one of the world's leading causes of death and disability in young adults, but its peripheral vascular consequences in humans are poorly understood. This prospective, monocentric, pathophysiological study aims to investigate differences in vasoreactivity in the anterior aspect of the contralateral forearm at the most injured cerebral hemisphere between patients with severe head trauma and patients with severe trauma without associated brain injury matched on sex and age (+/- 5 years).

Detailed description

Severe brain injury (SBI) is one of the world's leading causes of death and disability in young adults. Its impact on cerebral vascularization is well known. At the systemic level, it induces transient dysfunctions that can develop into severe failures, even in cases of isolated SBI. Studies on a mouse model of SBI show alterations in peripheral vascular reactivity that persist over time and are linked to endothelial dysfunction, the mechanism of which is a decoupling of endothelial NO synthase in a context of systemic inflammation. However, no data are available regarding the peripheral vascular consequences of SBI in humans. The main objective of this prospective, monocentric, pathophysiological study is to determine whether the postocclusive hyperaemic response at the anterior surface of the contralateral forearm to the most injured cerebral hemisphere differs between patients with severe brain injury and patients with severe trauma without associated head injury matched on sex and age (+/- 5 years), by studying the amplitude of post-occlusive hyperaemia (maximum amplitude expressed as percentage of vasodilatation and area under the curve : AUC) as a function of the group.

Interventions

None listed

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Healthy volunteers : * Men and women, over 18 years of age * Affiliation to a social security scheme * Signed Consent Patients with Severe Brain Injury : * Male and female, over 18 years of age * Isolated severe brain injury, defined by an initial Glasgow score less than or equal to 8. * Affiliation to a social security scheme * Signed informed consent Severe traumatized patients without associated severe brain injury: * men and women, over 18 years of age * severe trauma, defined by an Injury Severity Score (ISS) ≥ 16. * absence of associated severe brain injury, defined by an initial Glasgow score less than or equal to 8. * affiliation to or beneficiary of a social security scheme * signed informed consent

Exclusion criteria

* Hypersensitivity to lidocaine and/or prilocaine or to amide type local anesthetics or to any of the excipients of the cream. * History of axillary lymph node dissection, trauma or axillary surgery * Prohibited treatments and procedures : * In patients with head trauma: ongoing treatment with systemic vasodilators (calcium channel blocker, milrinone). * In healthy volunteers: no treatment will be authorized other than paracetamol, hormone supplementation (contraceptive pill, hormone therapy, thyroid hormones). * Pregnant, parturient or breastfeeding women * Subject in a period of exclusion from another study, * Person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure, * Subject having exceeded the annual compensation threshold for testing * Subject cannot be contacted in case of emergency

Design outcomes

Primary

MeasureTime frameDescription
Post-occlusive hyperaemia0-60 daysMaximum amplitude expressed as percentage of vasodilation and area under the curve: AUC

Secondary

MeasureTime frameDescription
Post-occlusive hyperaemia with local anesthesia0-60 daysMaximum amplitude expressed as percentage of vasodilation and area under the curve: AUC
Current-Induced Hyperaemia with local anesthesia0-60 daysArea under the curve expressed as a percentage of the baseline.
Local thermal hyperaemia0-60 daysMaximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau.
Local thermal hyperaemia with local anesthesia0-60 daysMaximum amplitude of the initial peak expressed as a percentage of the baseline and area under the curve of the delayed plateau.
Current-Induced Hyperaemia0-60 daysArea under the curve expressed as a percentage of the baseline.
Transient venous post-compression hyperaemia0-60 daysArea under the curve and percentage change from baseline.
Study of vasoreactivity in patients with severe brain injury0-60 daysExtent of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in patients with severe brain injury.
Study of vasoreactivity in healthy subjectsStudy visitDescription of the magnitude of post-occlusive hyperaemia, current-induced hyperaemia, thermal hyperaemia and cold response in healthy subjects.
Flow amplitude after local cooling0-60 daysAmplitude of initial vasoconstriction averaged over 1 min around the lowest flow value during the first 5 minutes.

Countries

France

Contacts

Primary ContactJean-Luc Cracowski, Pr
JLCracowski@chu-grenoble.fr0476767856
Backup ContactManon Gabin, Intern
mgabin@chu-grenoble.fr0476767575

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026